Today, disease management for fibrodysplasia ossificans progressiva (FOP) is focused on care, no disease-specific treatment is available.1
Guidelines have been published to address symptomatic relief and the importance of avoiding invasive and traumatic interventions in patients with FOP as they trigger flare-ups and subsequent heterotopic ossification (HO).2,3
Care by a healthcare team with experience in treating patients with fibrodysplasia ossificans progressiva (FOP) can help ensure that patients are not put at unnecessary risk of extraskeletal bone formation caused by even minor soft tissue injury.
Information on fibrodysplasia ossificans progressiva (FOP) has grown significantly over the past 10-15 years.
Research is expanding what we know about the natural history of FOP, as well as disease mechanisms.